cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin
(LT). Vaccine 18:38–49.
3. Chong, C., M. Friberg, and J. D. Clements. 1998. LT(R192G), a non-toxic 28.
mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced
humoral and cellular immune responses associated with protection against
lethal oral challenge with Salmonella spp. Vaccine 16:732–740.
4. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of 29.
Escherichia coli heat-labile enterotoxin and effect on the induction of oral
tolerance in mice to unrelated protein antigens. Vaccine 6:269–277.
5. Connell, T. D., and R. K. Holmes. 1992. Molecular genetic analysis of 30.
ganglioside GD1b-binding activity of Escherichia coli type IIa heat-labile
enterotoxin by use of random and site-directed mutagenesis. Infect. Immun.
60:63–70.
6. Constant, S. L., and K. Bottomly. 1997. Induction of Th1 and Th2 CD4 T
cell responses: the alternative approaches. Annu. Rev. Immunol. 15:297. 31.
7. de Haan, L., W. R. Verwey, I. K. Feil, M. Holtrop, W. G. J. Hol, E. Ag- steribbe, and J. Wilschut. 1998. Role of GM1 binding in the mucosal im- munogenicity and adjuvant activity of the Escherichia coli heat-labile entero- 32.
toxin and its B subunit. Immunology 94:424–430.
8. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli
heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. 33.
Infect. Immun. 63:1617–1623.
9. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R.
Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin
lacking ADP-ribosyltransferase activity act as nontoxic mucosal adjuvant.
Proc. Natl. Acad. Sci. USA 92:1644–1648. 34.
10. Elson, C. O., and W. Ealding. 1984. Generalized systemic and mucosal
immunity in mice after mucosal stimulation with cholera toxin. J. Immunol.
35.
132:2736–2741.
11. Elson, C. O., and W. Ealding. 1985. Genetic control of the murine immune
response to cholera toxin. J. Immunol. 135:930–932.
12. Fukuta, S., J. L. Magnani, E. M. Twiddy, R. K. Holmes, and V. Ginsburg.
36.
1988. Comparison of the carbohydrate-binding specificities of cholera toxin
and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb.
Infect. Immun. 56:1748–1753.
13. Gizurarson, S. 1990. Animal models for intranasal drug delivery studies.
37.
Acta Pharm. Nord. 2:105–122.
14. Gizurarson, S., S.-I. Tamura, T. Kurata, K. Hasiguchi, and H. Ogawa. 1991.
The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal
38.
membrane. Vaccine 9:825–832.
15. Gizurarson, S., S. Tamura, C. Aizawa, and T. Kurata. 1992. Stimulation of
the transepithelial flux of influenza HA vaccine by cholera toxin B subunit.
39.
Vaccine 19:101–106.
16. Gluck, R., R. Mischler, P. Durrer, E. Furer, A. B. Lang, C. Herzog, and S. J.
Cryz, Jr. 2000. Safety and immunogenicity of intranasally administered in- activated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181:1129–
1132.
40.
17. Gluck, U., J.-O. Gebbers, and R. Gluck. 1999. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heatlabile toxin in adult volunteers. J. Virol. 73:7780–7786.
18. Griffiths, S. L., R. A. Finkelstein, and R. R. Critchley. 1986. Characterization
41.
of the receptor for cholera toxin and Escherichia coli heat-labile enterotoxin
in rabbit intestinal brush borders. Biochem. J. 238:313–322.
19. Gross, E. A., J. A. Swenberg, S. Fields, and J. A. Popp. 1982. Comparative 42.
morphometry of the nasal cavity in rats and mice. J. Anat. 135:83–88.
20. Guery, J.-C., F. Galbiati, S. Smiroldo, and L. Adorini,. 1996. Selective de- velopment of T helper (Th) 2 cells induced by continuous administration of
low dose soluble proteins to normal and 2-microglobulin-deficient BALB/c 43.
mice. J. Exp. Med. 183:485–497.
21. Guidry, J. J., L. Cardenas, E. Cheng, and J. D. Clements. 1997. Role of
receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia 44.
coli heat-labile enterotoxin. Infect. Immun. 65:4943–4950.
22. Harkema, J. R. 1991. Comparative aspects of nasal airway anatomy: relevance to inhalation toxicology. Toxicol. Pathol. 19:321–336. 45.
23. Hashigucci, K., H. Ogawa, T. Ishidate, R. Yamashita, H. Kamiya, K. Wa- tanabe, N. Hattori, T. Sato, Y. Suzuki, T. Nagamine, C. Aizawa, S.-I.
Tamura, T. Kurata, and A. Oya. 1995. Antibody responses in volunteers
induced by nasal influenza vaccine combined with Escherichia coli heat-labile 46.
enterotoxin B subunit containing a trace amount of holotoxin. Vaccine
14:113–119.
24. Holmes, R. K., E. M. Twiddy, and C. L. Pickett. 1986. Purification and 47.
characterization of type II heat-labile enterotoxin of Escherichia coli. Infect.
Immun. 53:464–473.
25. Holmgren, J., M. Lindblad, P. Fredman, L. Svennerholm, and H. Myrvold. 48.
1985. Comparison of receptors for cholera and Escherichia coli enterotoxins
in human intestine. Gastroenterology 89:27–35.
26. Holmgren, J., P. Fredman, M. Lindblad, and L. Svennerholm. 1982. Rabbit
intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin 49.
lacking affinity for cholera toxin. Infect. Immun. 38:424–433.
27. Jiang, M. M., A. Kirchgessner, M. D. Gershon, and A. Suprenant. 1993. 50.
